Drugs & Targets FDA approves Opdivo + cisplatin + gemcitabine for unresectable or metastatic urothelial carcinoma March 08, 2024Vol.50 No.10
Drugs & Targets FDA grants accelerated approval to Brukinsa for R/R follicular lymphoma March 08, 2024Vol.50 No.10
Drugs & Targets Elipses’s selective RET inhibitor EP0031/A400 granted Fast Track designation in NSCLC March 08, 2024Vol.50 No.10
Drugs & Targets FDA, industry actions end sales of PFAS in U.S. food packaging March 01, 2024Vol.50 No.09
Drugs & Targets FDA grants Epkinly priority review sBLA for difficult-to-treat R/R follicular lymphoma March 01, 2024Vol.50 No.09
Drugs & Targets FDA accepts BLA for Tevimbra for 1L treatment of G/GEJ cancers March 01, 2024Vol.50 No.09
First-ever commercial TIL therapy: How NCI, Iovance, and Moffitt achieved FDA approval February 23, 2024Vol.50 No.08By Matthew Bin Han Ong
Conversation with The Cancer Letter Steven Rosenberg, Friedrich Graf Finckenstein: FDA recognition of TIL therapy is the result of 40 years of research February 23, 2024Vol.50 No.08By Matthew Bin Han Ong
